Press Releases                                                               

Date	Title	Download
12.8.08	Vion Presents Additional Survival Data on Onrigin™ (Laromustine) Injection at ASH Annual Meeting
12.4.08	Vion to Present Survival Data on Laromustine at ASH Annual Meeting
12.2.08	Vion Adds Tanya Lewis to Senior Management Team
11.4.08	Vion Updates Conference Call Information
11.3.08	Vion Reports 2008 Second Quarter and Six-Month Results • Quarterly Conference Call to be Held Thursday November 6 at 8:30 a.m.
9.22.08	Vion Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine® in Combination with Induction Therapy in Poor Prognosis AML Patients
8.19.08	Vion Enters into Agreement with HOVON to Conduct a Phase III Clinical Trial of Cloretazine® in combination with Frontline AML and MDS Therapy
8.14.08	Vion is Delisted from Nasdaq Stock Market
8.4.08	Vion Reports 2008 Second Quarter and Six-Month Results • Quarterly Conference Call to be Held Thursday August 7 at 8:30 a.m.
6.13.08	Vion Announces Presentation of Data of Cloretazine® (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting
6.2.08	Vion Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine® (VNP40101M) in Acute Myelogenous Leukemia at the ASCO® Annual Meeting
6.2.08	Vion Announces Presentation of Data from Phase III Trial of Cloretazine® (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO® Annual Meeting
5.30.08	Vion To Present Clinical Data on Cloretazine® (VNP40101M) at the ASCO® Annual Meeting
5.8.08	Vion Announces Initiation of Clinical Trial of Cloretazine® (VNP40101M) in Combination with Cytarabine
5.8.08	Vion To Appeal Nasdaq Delisting
5.6.08	Vion to Host Conference Call To Discuss 2008 First Quarter Financial Results
5.5.08	Vion Reports 2008 First Quarter Results
4.15.08	Vion Files Plan With Nasdaq
3.26.08	Vion Receives Nasdaq Notice
3.17.08	Vion Reports 2007 Fourth Quarter and Year-End Results
3.14.08	Vion to Host Conference Call To Discuss 2007 Fourth Quarter and Year-End Financial Results
3.7.08	Vion Regains NASDAQ Listing Compliance
2.20.08	Vion to Implement a One-for-Ten Reverse Stock Split
2.15.08	Vion Pays Interest on 7.75% Convertible Senior Notes
2.13.08	Vion Holds Special Meeting of Stockholders
2.4.08	Vion Adds William Hahne, M.D. to Senior Management Team
1.8.08	Vion Announces FDA Lift of Clinical Hold on Phase III Study of Cloretazine® (VNP40101M) and Cytarabine in Relapsed AML

We hope we have provided you with answers to some of your questions. If you have a specific question please contact us.